Pediatric Gastroenterology, Hepatology & Nutrition

  • 제27권2호
  • /
  • Pages.104-112
  • /
  • 2024
  • /
  • 2234-8646(pISSN)
  • /
  • 2234-8840(eISSN)
대한소아소화기영양학회 (The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition)
권호 표지
DOI QR코드

DOI QR Code

Incidence of Low Seroimmunity to Hepatitis B Virus in Children with Inflammatory Bowel Disease: A Single Center Experience

  • Hala H. Mansour (Department of Pediatrics, Faculty of Medicine, Cairo University) ;
  • Ayman E. Eskander (Department of Pediatrics, Faculty of Medicine, Cairo University) ;
  • Sara M. Osman (Department of Pediatrics, Faculty of Medicine, Cairo University) ;
  • Normeen H. Rady (Department of Clinical Pathology, Faculty of Medicine, Cairo University)
  • 투고 : 2023.01.13
  • 심사 : 2023.11.27
  • 발행 : 2024.03.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Immunosuppressive therapy is frequently administered to patients with inflammatory bowel disease (IBD), which may make them more susceptible to infections like hepatitis B. Methods: A cross-sectional study was conducted on patients aged 5-18 years diagnosed with IBD who visited a gastroenterology clinic along with controls who were the same age as the patients with IBD and were healthy overall. A logistic regression analysis using the independent variables of age, sex, race, disease phenotype, surgery, and medications and the dependent variable of adequate hepatitis B surface antibody (HBsAb) titers (>10 mIU/mL) was performed on quantitative serum HBsAb titers. Results: The study enrolled 62 patients, including 37 males and 25 females. Crohn's disease, ulcerative colitis, and indeterminate colitis were diagnosed in 16, 22, and 24 patients, respectively. Thirty-nine patients were taking corticosteroids at the time of the study, 42 were taking immunomodulators, and four were taking biologics. Compared to 44.7% of the control group, 9.3% of the patients had protective titers. Only 12 out of 62 patients had HBsAb titers greater than 10 million IU/mL. None of the patients who received biologics or corticosteroids and 3.2% of those who received immunomodulators were found to be seroimmuned. Conclusion: The younger patients had the highest titers. Patient-specific factors that may impact these low titers include the length of the patient's illness and the use of immunosuppressants.

키워드

참고문헌

  1. Shikhare G, Kugathasan S. Inflammatory bowel disease in children: current trends. J Gastroenterol 2010;45:673-82. https://doi.org/10.1007/s00535-010-0241-5
  2. Millonig G, Kern M, Ludwiczek O, Millonig G, Kern M, Ludwiczek O. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12:974-6. https://doi.org/10.3748/wjg.v12.i6.974
  3. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, et al.; Study Group. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005;366:1379-84. https://doi.org/10.1016/S0140-6736(05)67568-X
  4. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9. https://doi.org/10.1002/ibd.20035
  5. Ali T, Yun L, Shapiro D, Madhoun MF, Bronze M. Viral infections in patients with inflammatory bowel disease on immunosuppressants. Am J Med Sci 2012;343:227-32. https://doi.org/10.1097/MAJ.0b013e31821ff728
  6. Musa RB, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, et al. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol 2014;20:15358-66. https://doi.org/10.3748/wjg.v20.i41.15358
  7. Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis 2011;17:2536-40. https://doi.org/10.1002/ibd.21667
  8. Watts A, Bennett WE, Molleston JP, Gupta SK, Croffie JM, Waseem S, et al. Incidence of low seroimmunity to hepatitis B virus in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2017;65:551-4. https://doi.org/10.1097/MPG.0000000000001580
  9. Moses J, Alkhouri N, Shannon A, Raig K, Lopez R, Danziger-Isakov L, et al. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol 2012;107:133-8. https://doi.org/10.1038/ajg.2011.295
  10. Musa RB, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, et al. Hepatitis B vaccination in patients with inflammatory bowel disease. World journal of gastroenterology. World J Gastroenterol 2014;20:15358-66. https://doi.org/10.3748/wjg.v20.i41.15358
  11. Jiang H, Wang S, Deng M, Li YC, Ling ZX, Shao L, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine 2017;35:2633-41.  https://doi.org/10.1016/j.vaccine.2017.03.080
  12. Belle A, Baumann C, Bigard MA, Zallot C, Gizard E, Gueant JL, et al. Impact of immuno-suppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2015;27:877-81. https://doi.org/10.1097/MEG.0000000000000370
  13. Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol 2015;30:1591-5. https://doi.org/10.1111/jgh.13001
  14. Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis 2016;24:16-22. https://doi.org/10.1093/infdis/jiv748